CRST Oy
CRST Oy is a Finnish contract research organization (CRO) founded from an academic service unit with ~25–30 years of experience in clinical drug development. The company provides full-service and site-based support for early-phase (including first-in-human and Phase I) and later-phase clinical trials, with expertise in clinical pharmacology, PK/PD, imaging studies and subject recruitment via research units in Turku and Helsinki. CRST operates under SOP-based quality systems in line with ICH GCP and offers regulatory, data management, and bioanalytical support.
Industries
N/A
Nr. of Employees
small (1-50)
Services
Design-to-report services for Phase I and first-in-human studies including SAD/MAD, safety monitoring, PK/PD, subject recruitment and IMP handling.
Site and supporting services in Finland for Phase II–IV studies including project management, recruitment, clinical conduct, IMP management and imaging services.
Preparation of regulatory submissions, ethical committee applications and medical writing of protocols, informed consent forms and study reports.
Project management, study monitoring and site management services delivered by experienced clinical operations personnel.
Laboratory testing and bioanalytical services for safety and pharmacology endpoints provided in-house or via partners.
Execution of imaging endpoints and collaboration on PET tracer development to support target engagement, biodistribution and dose selection.
Design-to-report services for Phase I and first-in-human studies including SAD/MAD, safety monitoring, PK/PD, subject recruitment and IMP handling.
Site and supporting services in Finland for Phase II–IV studies including project management, recruitment, clinical conduct, IMP management and imaging services.
Preparation of regulatory submissions, ethical committee applications and medical writing of protocols, informed consent forms and study reports.
Project management, study monitoring and site management services delivered by experienced clinical operations personnel.
Laboratory testing and bioanalytical services for safety and pharmacology endpoints provided in-house or via partners.
Execution of imaging endpoints and collaboration on PET tracer development to support target engagement, biodistribution and dose selection.
Expertise Areas
- Early-phase clinical pharmacology and first-in-human trials
- Clinical trial management and site services
- Pharmacokinetics / pharmacodynamics
- Imaging studies and PET tracer development
Key Technologies
- PET imaging
- fMRI and MRI imaging
- CT imaging
- Clinical PK/PD modelling and pharmacokinetic calculations
News & Updates
Announcement of acquisition by LINK Medical AS; describes CRST as a Finnish CRO with two early-phase clinics and expertise in FIH and Phase I studies.
Contract announcement for a first-in-human trial of a small-molecule fractalkine-targeting candidate primarily intended for cancer indications.
Summary noting CRST investigators' contribution to a Phase Ib study on intrathecal antisense oligonucleotide (MAPTRx) reported in Nature Medicine.
Announcement of appointment of a new Chief Scientific Officer with extensive clinical pharmacology experience.
Multiple scientific publications and contributions to peer-reviewed studies in areas including PET imaging, PK/PD, CNS and metabolic disease research (selected publications listed on site).
Company-affiliated investigator nominated as Clinical Investigator of the Year 2022.
Announcement of acquisition by LINK Medical AS; describes CRST as a Finnish CRO with two early-phase clinics and expertise in FIH and Phase I studies.
Contract announcement for a first-in-human trial of a small-molecule fractalkine-targeting candidate primarily intended for cancer indications.
Summary noting CRST investigators' contribution to a Phase Ib study on intrathecal antisense oligonucleotide (MAPTRx) reported in Nature Medicine.
Announcement of appointment of a new Chief Scientific Officer with extensive clinical pharmacology experience.
Multiple scientific publications and contributions to peer-reviewed studies in areas including PET imaging, PK/PD, CNS and metabolic disease research (selected publications listed on site).
Company-affiliated investigator nominated as Clinical Investigator of the Year 2022.